Correlation Between Structure Therapeutics and Veracyte

Can any of the company-specific risk be diversified away by investing in both Structure Therapeutics and Veracyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Structure Therapeutics and Veracyte into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Structure Therapeutics American and Veracyte, you can compare the effects of market volatilities on Structure Therapeutics and Veracyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Structure Therapeutics with a short position of Veracyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Structure Therapeutics and Veracyte.

Diversification Opportunities for Structure Therapeutics and Veracyte

0.38

Correlation Coefficient

Structure Therapeutics  Veracyte

Weak diversification

The 3 months correlation between Structure and Veracyte is 0.38. Overlapping area represents the amount of risk that can be diversified away by holding Structure Therapeutics America and Veracyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Veracyte and Structure Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Structure Therapeutics American are associated (or correlated) with Veracyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Veracyte has no effect on the direction of Structure Therapeutics i.e., Structure Therapeutics and Veracyte go up and down completely randomly.

Pair Corralation between Structure Therapeutics and Veracyte

Given the investment horizon of 90 days Structure Therapeutics American is expected to generate 1.97 times more return on investment than Veracyte. However, Structure Therapeutics is 1.97 times more volatile than Veracyte. It trades about 0.06 of its potential returns per unit of risk. Veracyte is currently generating about 0.04 per unit of risk. If you would invest  1,500  in Structure Therapeutics American on August 13, 2024 and sell it today you would earn a total of  2,302  from holding Structure Therapeutics American or generate 153.47% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	90.3%
Values	Daily Returns

Structure Therapeutics America  vs.  Veracyte

Structure Therapeutics

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Structure Therapeutics American are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating fundamental indicators, Structure Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Veracyte

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Structure Therapeutics and Veracyte

The main advantage of trading using opposite Structure Therapeutics and Veracyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Structure Therapeutics position performs unexpectedly, Veracyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Veracyte will offset losses from the drop in Veracyte's long position.

The idea behind Structure Therapeutics American and Veracyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.